Teva Pharmaceutical Industries Ltd Receives FDA Approval for Interchangeable Biosimilar
Teva Pharmaceutical Industries Ltd has received FDA approval for the interchangeability of SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults. This approval was granted in collaboration with Alvotech.
The approved indication includes the treatment of:
- Moderate to severe plaque psoriasis
- Active psoriatic arthritis in adults
This development is expected to have a positive impact on the company’s stock price, which has been trading higher on Monday.
Financial Performance
The company’s financial performance for the quarter ended March 31, 2025 has been reported, but the details are not provided in this summary.